1,420 results on '"Cortes, Jorge E."'
Search Results
2. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
3. Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.
4. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
5. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
6. Navigating disparities: Insights from a colorectal cancer screening program in federally qualified community healthcare centers.
7. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
8. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group
9. Project Confirm: Accelerated Drug Approvals for CML—Response
10. Clinical Trials with Nucleoside Analogs in Other Hematologic Malignancies
11. Defining the Optimal Dose Schedule of Purine Analogs and Assessment of Response
12. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
13. Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review
14. POSTER: CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
15. CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
16. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
17. Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
18. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers
19. Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing report
20. Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
21. Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
22. Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
23. Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
24. Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
25. Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
26. Supplemental Table 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
27. Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
28. SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
29. Supplementary Figures 1 - 8 from Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
30. Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
31. Supplemental Figure 2 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
32. Supplementary Figures 1 - 8 from Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
33. SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
34. Supplemental Figure 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
35. Data from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
36. Supplementary Methods and Figures and Table from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
37. Data from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
38. Supplementary Methods and Figures and Table from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
39. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
40. Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase
41. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
42. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
43. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
44. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
45. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial
46. Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
47. Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience
48. Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
49. Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
50. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.